Sobi celebrates 25 years with Orfadin® (nitisinone) - a result of ground-breaking Swedish research
(Thomson Reuters ONE) -
To acknowledge that it is 25 years since the first person with the rare genetic
disease Hereditary Tyrosinaemia type 1 (HT-1) was treated in clinical trials
with Orfadin® (nitisinone), Swedish Orphan Biovitrum AB (publ) (Sobi) (STO:
SOBI) hosted a satellite symposium in Lyon, France in conjunction with the
annual SSIEM symposium, Society for the Study of Inborn Errors of Metabolism.
HT-1 is a progressive disease that affects infants and children, may result in
liver and kidney failure and can be fatal if it is not diagnosed and treated
early in life.
The symposium honoured Professor Elisabeth Holme and Professor Sven Lindstedt,
two Swedish pioneers in the research of HT-1, both of whom passed away earlier
this year. Professor Lindstedt led a group at University of Gothenburg who
developed and presented ground-breaking research into HT-1. He and his group
established the primary aetiology behind the disease, which led to the discovery
of nitisinone. Today Orfadin® (nitisinone) is first line therapy, having
replaced liver transplantation, as standard care.
"Thanks to these visionary individuals and to the conduct of research that led
to the development of nitisinone, people with HT-1 who 25 years ago had short
life expectancy as a consequence of the natural course of the disease, have the
possibility of therapeutic intervention that may even allow them to become
grandparents", says Birgitte Volck, Chief Medical Officer of Sobi.
Before pharmacological treatment was available, less than one third of infants
diagnosed with HT-1 before two months of age lived past their second
birthday.([1]) Treatment with Orfadin, combined with dietary restriction of
tyrosine and phenylalanine; and more widespread new-born screening leading to
early diagnosis have dramatically improved the outcomes for HT-1 patients.([2])
Orfadin is approved in the EU, USA and several other countries for the treatment
of patients with confirmed diagnosis of hereditary tyrosinaemia type 1 (HT-1) in
combination with dietary restriction of tyrosine and phenylalanine. HT-1 is a
progressive disease where the body lacks the ability to break down the amino
acid tyrosine. Without treatment, HT-1 is ultimately fatal. Orfadin, together
with the appropriate diet, is an essential part of effective HT-1 treatment.
---
About Orfadin
Orfadin (nitisinone) blocks the breakdown of tyrosine, thereby reducing the
amount of toxic by-products in the body. People with Hereditary Tyrosinaemia
type-1 (HT-1) have problems breaking down an amino acid called tyrosine. Toxic
by-products are formed and accumulate in the body, which can cause liver
failure, renal dysfunction and neurological complications. In the most common
form of the disease, symptoms arise within the first six months of the child's
life. Patients must maintain a special diet in combination with Orfadin
treatment as tyrosine remains in the body. Approximately 1,000 persons are
identified as living with HT-1 today. Orfadin is a proprietary product and is
developed by and marketed globally by Sobi.
About Sobi
Sobi is an international specialty healthcare company dedicated to rare
diseases. Our mission is to develop and deliver innovative therapies and
services to improve the lives of patients. The product portfolio is primarily
focused on Haemophilia, Inflammation and Genetic diseases. We also market a
portfolio of specialty and rare disease products for partner companies across
Europe, the Middle East, North Africa and Russia. Sobi is a pioneer in
biotechnology with world-class capabilities in protein biochemistry and
biologics manufacturing. In 2014, Sobi had total revenues of SEK 2.6 billion
(USD 380 M) and about 600 employees. The share (STO: SOBI) is listed on NASDAQ
OMX Stockholm. More information is available at www.sobi.com.
For more information please contact
Media relations Investor relations
Oskar Bosson, Head of Jörgen Winroth, Vice President, Head of Investor
Communications Relations
T: +46 70 410 71 80 T: +1 347-224-0819, +1 212-579-0506, +46 8 697 2135
oskar.bosson(at)sobi.com jorgen.winroth(at)sobi.com
([1]) van Spronsen FJ, Thomasse Y, Smit GP, et al. Hepatology.
1994; 20(5):1187-1191
([2]) Orfadin EPAR: Product information 25/07/2015 Orfadin -EMEA/H/C/000555
-IB/004
031e_25 years with Orfadin:
http://hugin.info/134557/R/1949732/708697.pdf
This announcement is distributed by GlobeNewswire on behalf of
GlobeNewswire clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Swedish Orphan Biovitrum AB (publ) via GlobeNewswire
[HUG#1949732]
Unternehmensinformation / Kurzprofil:
Datum: 04.09.2015 - 08:00 Uhr
Sprache: Deutsch
News-ID 418064
Anzahl Zeichen: 5483
contact information:
Town:
Stockholm
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 286 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Sobi celebrates 25 years with Orfadin® (nitisinone) - a result of ground-breaking Swedish research"
steht unter der journalistisch-redaktionellen Verantwortung von
Swedish Orphan Biovitrum AB (publ) (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
